BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther 2020;51:1031-8. [PMID: 32329532 DOI: 10.1111/apt.15719] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 2020;55:141-50. [PMID: 33254032 DOI: 10.1016/j.coph.2020.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Verstockt B, Vetrano S, Salas A, Nayeri S, Duijvestein M, Vande Casteele N, Danese S, D’haens G, Eckmann L, Faubion WA, Feagan BG, Jairath V, Ma C, Mcgovern D, Panes J, Sandborn WJ, Silverberg MS, Vermeire S; Alimentiv Translational Research Consortium (ATRC). Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. [DOI: 10.1038/s41575-021-00574-7] [Reference Citation Analysis]
3 Judge C, Saeidi R, Sugrue K, Rabbitt L, Keogh A, Byron C, Zulquernain SA, Gleeson S, O'Toole A, Buckley M, Slattery E, Doherty G, McCarthy J. Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era? Inflamm Bowel Dis 2021;27:956-9. [PMID: 33544119 DOI: 10.1093/ibd/izab028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fumery M, Yzet C, Brazier F. Letter: combination of biologics in inflammatory bowel diseases. Aliment Pharmacol Ther 2020;52:566-7. [DOI: 10.1111/apt.15891] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, Chang S, Axelrad JE. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022:izac035. [PMID: 35262671 DOI: 10.1093/ibd/izac035] [Reference Citation Analysis]
6 Kang EA, Jang J, Choi CH, Kang SB, Bang KB, Kim TO, Seo GS, Cha JM, Chun J, Jung Y, Kim HG, Im JP, Kim S, Ahn KS, Lee CK, Kim HJ, Kim MS, Park DI. Development of a Clinical and Genetic Prediction Model for Early Intestinal Resection in Patients with Crohn's Disease: Results from the IMPACT Study. J Clin Med 2021;10:633. [PMID: 33562363 DOI: 10.3390/jcm10040633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Dolinger MT, Spencer EA, Lai J, Dunkin D, Dubinsky MC. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:1210-4. [PMID: 33125058 DOI: 10.1093/ibd/izaa277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yu N, Sarwal D, Ash R, Aslinia FM. Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual. BMJ Case Rep 2021;14:e243500. [PMID: 34645625 DOI: 10.1136/bcr-2021-243500] [Reference Citation Analysis]
9 Yzet C, Brazier F, Sabbagh C, Fumery M. Managing complex perianal disease after anti-TNF failure: Where to go next? Current Research in Pharmacology and Drug Discovery 2022;3:100081. [DOI: 10.1016/j.crphar.2022.100081] [Reference Citation Analysis]
10 Chen P, Huang S, Yu Q, Chao K, Wang Y, Zhou G, Zhuang X, Zeng Z, Chen M, Zhang S. Serum exosomal microRNA-144-3p: a promising biomarker for monitoring Crohn's disease. Gastroenterology Report 2021. [DOI: 10.1093/gastro/goab056] [Reference Citation Analysis]
11 Mas EB, Calvo XC. Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients. JCM 2022;11:1076. [DOI: 10.3390/jcm11041076] [Reference Citation Analysis]
12 Hilley P, Gilmore R, Srinivasan A, Choy M, De Cruz P. Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis. Inflamm Bowel Dis 2021:izab095. [PMID: 33999191 DOI: 10.1093/ibd/izab095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00344-X. [PMID: 33798711 DOI: 10.1016/j.cgh.2021.03.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576 [DOI: 10.12998/wjcc.v10.i8.2569] [Reference Citation Analysis]
15 Alayo QA, Khatiwada A, Patel A, Zulfiqar M, Gremida A, Gutierrez A, Rood RP, Ciorba MA, Christophi G, Deepak P. Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021:izab112. [PMID: 34037225 DOI: 10.1093/ibd/izab112] [Reference Citation Analysis]
16 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis 2021:jjab206. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Reference Citation Analysis]
18 Lin XX, Qiu Y, Zhuang XJ, Liu F, Wu XM, Chen MH, Mao R. Intestinal stricture in Crohn's disease: A 2020 update. J Dig Dis 2021;22:390-8. [PMID: 34014617 DOI: 10.1111/1751-2980.13022] [Reference Citation Analysis]
19 Eronen H, Kolehmainen S, Koffert J, Koskinen I, Oksanen P, Jussila A, Huhtala H, Sipponen T, Ilus T. Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. Scand J Gastroenterol 2022;:1-6. [PMID: 35238727 DOI: 10.1080/00365521.2022.2045350] [Reference Citation Analysis]
20 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
21 Dimopoulos C, Al-Bawardy B. SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn's Disease. Inflamm Bowel Dis 2020;26:e153-4. [PMID: 33043966 DOI: 10.1093/ibd/izaa275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S, Rahier JF; European COMBIO study group. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. United European Gastroenterol J 2021. [PMID: 34694746 DOI: 10.1002/ueg2.12170] [Reference Citation Analysis]
23 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
24 Lee SD, Singla A, Harper J, Barahimi M, Jacobs J, Kamp KJ, Clark-Snustad KD. Safety and Efficacy of Tofacitinib in Combination With Biologic Therapy for Refractory Crohn's Disease. Inflamm Bowel Dis 2021:izab176. [PMID: 34347103 DOI: 10.1093/ibd/izab176] [Reference Citation Analysis]
25 Haider M, Lashner B. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. J Clin Gastroenterol 2021;55:661-6. [PMID: 34238847 DOI: 10.1097/MCG.0000000000001583] [Reference Citation Analysis]
26 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
27 Abdulla M, Chew TS. Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease. Curr Opin Gastroenterol 2021;37:275-83. [PMID: 33769380 DOI: 10.1097/MOG.0000000000000729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Reference Citation Analysis]
30 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Tse CS, Dulai PS. Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease. Gastroenterol Clin North Am 2022;51:283-98. [PMID: 35595415 DOI: 10.1016/j.gtc.2021.12.005] [Reference Citation Analysis]
32 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
33 D'Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm. J Crohns Colitis 2022;16:ii30-41. [PMID: 35553665 DOI: 10.1093/ecco-jcc/jjac011] [Reference Citation Analysis]
34 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
35 Privitera G, Onali S, Pugliese D, Renna S, Savarino E, Viola A, Ribaldone DG, Buda A, Bezzio C, Fiorino G, Fantini MC, Scaldaferri F, Guidi L, Danese S, Gasbarrini A, Orlando A, Armuzzi A. Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease. J Crohns Colitis 2020:jjaa149. [PMID: 32674156 DOI: 10.1093/ecco-jcc/jjaa149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]